Y-mAbs' naxitamab shows promise in treating high-risk neuroblastoma. Explore its phase 2 success, strong cash runway, and ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to ...

Shares of Genmab A/S (GMAB) fell this week after partner Johnson & Johnson (JNJ) unsurprisingly opted out of the deal to develop and commercialize GEN3014, Genmab’s next-generation CD38 HexaBody ...

and an anti-CD38 monoclonal antibody. As a personalised medicine, CARVYKTI treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

GSK had great expectations for Blenrep, which was approved in 2020 for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and ...